Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hwangryun pharmacoacupuncture is a distilled herbal medicine extract developed by Jaseng Hospital of Korean Medicine. It is derived from *Coptis chinensis* (Hwangryun) and is administered via injection into specific acupoints, a practice known as pharmacoacupuncture. This modality combines traditional acupuncture techniques with the pharmacological effects of herbal extracts. In a Phase 3 clinical trial (NCT02196129), it was used as a control treatment to assess the immediate pain-relieving efficacy of Sinbaro-3 in patients suffering from moderate to severe low back pain associated with herniated intervertebral discs. The treatment protocol involves the administration of 1cc of the distilled extract across six acupoints at the site of pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hwangryun pharmacoacupuncture.